옵션 체인은 다양한 행사가격과 만기일에 대한 Magic Empire Glb의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Magic Empire Glb에 대한 시장 심리를 평가합니다..

Magic Empire Glb (NASDAQ:MEGL) 주식, 옵션 체인

Magic Empire Global

Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.

Magic Empire Global Limited - Class A Ordinary Shares

Magic Empire Global Ltd

UBS analyst Joshua Spector maintains CF Industries Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) with a Neutral and raises the price target from $79 to $82.

News

Price Target

Analyst Ratings

UBS Maintains Neutral on CF Industries Holdings, Raises Price Target to $82

RBC Capital analyst Maurice Choy maintains Atco (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACO#TSX">ACO</a>) with a Sector Perform and raises the price target from C$51 to C$53.

TSX:ACO

TSX:ACO/X

RBC Capital Maintains Sector Perform on Atco, Raises Price Target to C$53

While Steven Madden Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) reported a "significant" earnings beat on Wednesday, Telsey Advisory Group reported that the company withdrew its full-year guidance due to tariff-related uncertainty.
The Steven Madden Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5888c53977f9dd0001877a22/dana-telsey">Analyst Dana Telsey</a> maintained a Market Perform rating and price of $24.
The Steven Madden Thesis: The company completed the acquisition of Kurt Geiger, which nicely complements the existing business as "it skews higher end and more towards handbags," Telsey said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Management withdrew its 2025 guidance, due to uncertainty associated with tariffs, which was not surprising given the company's exposure to China for sourcing, she added.
The analyst highlighted that Steven Madden plans to follow a three-pronged tariff mitigation strategy:
<ul>
<li>Moving production out of China</li>
<li>Negotiating with suppliers for price concessions</li>
<li>Taking price on products</li>
</ul>
Management indicated that these changes would position the company for long-term growth, she stated.
"Overall, we believe SHOO has been bringing trend-right products to market quickly, growing its apparel and accessories business, and expanding internationally," Dana further wrote.
SHOO Price Action: Shares of Steven Madden had risen by 2% to $23.90 at the time of publication Thursday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/44019170/steve-madden-faces-looming-margin-pressure-and-tariff-headwinds-analyst-predicts-tough-road-ahead">Steve Madden Faces Looming Margin Pressure And Tariff Headwinds, Analyst Predicts Tough Road Ahead</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings Beats

Reiteration

Movers

Trading Ideas

SHOO

Steven Madden's 3-Pronged Tariff Mitigation Plan Stands Out To Analyst

Consumer health company&nbsp;Kenvue Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) on Thursday reported first-quarter 2025 sales of $3.74 billion, beating the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of $3.68 billion</a>.
<ul>
<li>Sales decreased 3.9% year over year, reflecting a 1.2% organic sales decline and a 2.7% foreign currency headwind.</li>
<li>The organic sales decline was driven by 0.3% unfavorable value realization, reflecting planned strategic price investments, and a <a href="https://www.benzinga.com/pressreleases/25/05/b45280440/kenvue-reports-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">0.9% volume decline</a>.</li>
</ul>
Some of Kenvue's most iconic brands include Aveeno, BAND-AID Brand, Johnson&#8217;s, Listerine, Neutrogena, and Tylenol.
Gross profit margin was 58.0% vs. 57.6% a year ago. Adjusted gross profit margin&nbsp;contracted 20 basis points vs. the prior year period to 60%.
Also Read: <a href="https://www.benzinga.com//node/45020318">What Is The Tariff Risk For Procter &amp; Gamble? Analyst Calculates, Trims Outlook</a>
Operating income margin was 14.9% vs. 14.1%. Adjusted operating income margin&nbsp;was 19.8% vs. 22.0% in the prior year period.
The self-care segment recorded $1.67 billion in net sales, almost flat year over year. The skin health and beauty segment recorded a 7% drop in first-quarter net sales to $977 million. Essential Health segment sales decreased around 4% to&nbsp;$1.09 billion.
&#8220;In Q1, our teams executed our plans while continuing to navigate an evolving macro and consumer environment,&#8221; said Thibaut Mongon, CEO. &#8220;We are committed and focused on activating our brands while staying agile and flexible to accelerate sustainable, profitable growth.&#8221;
Guidance:&nbsp;Kenvue updated its fiscal 2025 outlook to reflect current foreign exchange rates and the estimated impact of higher costs due to tariffs. The company expects:
<ul>
<li>Net sales increase of +1% to +3% (-1% to +1% prior) year-over-year, with organic sales growth of +2% to +4 (unchanged) and a ~1% headwind from foreign currency translation (earlier expected around 3%).</li>
<li>Adjusted operating income margin is expected to decline year over year, reflecting the estimated impact of tariffs. Earlier, the company expected improvement year over year.</li>
<li>Adjusted diluted earnings per share are expected to be about flat year over year, including a low-single-digit negative impact from foreign currency. In February, Kenvue expected flat to +2% year-over-year Adjusted diluted earnings per share growth, including a mid-single-digit unfavorable <a href="https://www.benzinga.com/pressreleases/25/02/b43523300/kenvue-reports-full-year-and-fourth-quarter-2024-results" target="_blank" rel="noreferrer noopener">impact from foreign currency</a>.</li>
</ul>
The company is working to reduce tariffs&#8217; financial impact through several mitigation actions. 
On Thursday, Kenvue appointed Amit Banati as the company&#8217;s CFO, effective May 12, 2025. Mr. Banati will <a href="https://www.benzinga.com/pressreleases/25/05/b45280347/kenvue-announces-chief-financial-officer-transition" target="_blank" rel="noreferrer noopener">succeed Paul Ruh</a>.
In April, Kenvue announced a five-year collaboration with Microsoft to establish a strong foundation for transforming digital operations through advanced <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44834009/kenvue-announces-5-year-collaboration-with-microsoft-to-transform-digital-operations" rel="noreferrer noopener">Artificial Intelligence (AI) technologies</a>.
These technologies include machine-enabled collaboration, predictive analytics, smart agents, digital twins, and generative AI. By advancing predictive and AI-assisted capabilities, Kenvue aims to deliver enhanced consumer experiences, increased productivity, and sustained growth.
Over the next five years, Kenvue will scale its use of Microsoft Azure to capitalize on its wide range of services, including data analytics and AI.
Price Action:&nbsp;KVUE stock is up 6.30% at $24.57 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/05/45285116/skyworks-stock-heads-lower-despite-q2-profit-sales-victory" target="_blank" rel="noreferrer noopener">Skyworks Stock Heads Lower Despite Q2 Profit, Sales Victory</a></li>
</ul>
Photo by Colleen Michaels via Shutterstock

Earnings

Guidance

Health Care

General

KVUE

Neutrogena-Maker Kenvue Beats Profit Forecast, Ups Sales Outlook

WIIM

GPUS

Hyperscale Data shares are trading higher. The stock has been volatile after the company recently issued Q1 and FY25 sales guidance.

RBC Capital analyst Ryland Conrad maintains Premium Brands Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PBH#TSX">PBH</a>) with a Sector Perform and raises the price target from C$97 to C$99.

TSX:PBH

RBC Capital Maintains Sector Perform on Premium Brands Hldgs, Raises Price Target to C$99

UBS analyst Josh Silverstein maintains California Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRC#NYSE">CRC</a>) with a Buy and raises the price target from $49 to $51.

UBS Maintains Buy on California Resources, Raises Price Target to $51

UBS analyst Joshua Spector maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Buy and raises the price target from $74 to $76.

CTVA

UBS Maintains Buy on Corteva, Raises Price Target to $76

RBC Capital analyst Andrew Wong upgrades Ag Growth International (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AFN#TSX">AFN</a>) from Sector Perform to Outperform and raises the price target from C$40 to C$50.

Upgrades

TSX:AFN

RBC Capital Upgrades Ag Growth International to Outperform, Raises Price Target to C$50

UBS analyst Michael Lasser maintains National Vision Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) with a Buy and raises the price target from $18 to $20.

UBS Maintains Buy on National Vision Holdings, Raises Price Target to $20

UBS analyst Eric Beaumont maintains Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) with a Neutral and raises the price target from $52 to $56.

UBS Maintains Neutral on Nutrien, Raises Price Target to $56

JBLU

Shares of airline stocks are higher. The Trump administration has reportedly proposed its new air traffic control system plans.

UBS analyst Taylor McGinnis maintains Bentley Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSY#NASDAQ">BSY</a>) with a Neutral and raises the price target from $48 to $53.

UBS Maintains Neutral on Bentley Systems, Raises Price Target to $53

RBC Capital analyst Ken Herbert maintains VSE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEC#NASDAQ">VSEC</a>) with a Outperform and raises the price target from $140 to $150.

VSEC

RBC Capital Maintains Outperform on VSE, Raises Price Target to $150

UBS analyst Lloyd Walmsley maintains Tripadvisor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) with a Neutral and raises the price target from $15 to $16.

TRIP

UBS Maintains Neutral on Tripadvisor, Raises Price Target to $16

Vor Biopharma shares are trading lower after the company announced a wind down and 95% workforce reduction.

RBC Capital analyst Brad Erickson maintains Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Outperform and raises the price target from $82 to $94.

UBER

RBC Capital Maintains Outperform on Uber Technologies, Raises Price Target to $94

ARHS

Arhaus shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 sales guidance.

UBS analyst Karl Keirstead maintains Informatica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFA#NYSE">INFA</a>) with a Neutral and raises the price target from $19 to $20.

INFA

UBS Maintains Neutral on Informatica, Raises Price Target to $20

ASST

Asset Entities shares are trading higher after the company announced it entered into a merger agreement with Strive Asset Management.

Press Releases

Magic Empire Global Limited Announces Receipt of Nasdaq Notification of additional 180 calendar day period to regain compliance of minimum bid price requirement

Magic Empire Global Limited Announces First Half 2024 Unaudited Financial Results

Magic Empire Global Limited announces that the bid price deficiency concern raised by Nasdaq has been successfully resolved

MEGL

AMTD IDEA Group American Depositary Shares, each representing six (6) Class A Ordinary Shares

Comments

Magic Empire Glb

Magic Empire Glb (MEGL) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌